Li Ming, Han Shuangyin, Shi Xiwen
Department of Neurosurgery, The People's Hospital of Zhengzhou University, 7 Weiwu Road, Zhengzhou City, Henan Province, 450003, People's Republic of China.
Tumour Biol. 2016 Feb;37(2):1797-801. doi: 10.1007/s13277-015-3958-1. Epub 2015 Aug 29.
Glioma is one of the greatest threats to human health, and invasive growth of glioma is its major cause of death. Inhibiting or blocking angiogenesis can effectively inhibit tumor growth and metastasis or dramatically reduce the size of the original lesion. Therefore, anti-angiogenic therapy has currently become the most promising treatment strategy for glioma. Although dendritic cells (DCs) used in DC-based immunotherapy are loaded with tumor-associated antigens, the anti-tumor immune response is effectively stimulated in cytotoxic specific T lymphocytes (CTLs), thereby achieving targeted killing of tumor cells without harming surrounding normal cells. This makes it a highly promising new form of therapy. This article reviews the existing evidence regarding in situ DC vaccination for the treatment of glioma and puts forward hypotheses regarding patient, tumor, and technical factors and warrant further investigation.
胶质瘤是对人类健康的最大威胁之一，而胶质瘤的侵袭性生长是其主要死因。抑制或阻断血管生成可有效抑制肿瘤生长和转移，或显著缩小原发灶大小。因此，抗血管生成疗法目前已成为治疗胶质瘤最具前景的治疗策略。尽管基于树突状细胞（DC）的免疫疗法中使用的DC负载了肿瘤相关抗原，但在细胞毒性特异性T淋巴细胞（CTL）中可有效刺激抗肿瘤免疫反应，从而实现对肿瘤细胞的靶向杀伤而不损害周围正常细胞。这使其成为一种极具前景的新型治疗方式。本文综述了关于原位DC疫苗治疗胶质瘤的现有证据，并提出了关于患者、肿瘤和技术因素的假设，值得进一步研究。
